Polycyclic compound, preparation methods and medicinal uses thereof
WO2025092986A1PCT designated stage expired Publication Date: 2025-05-08JIANGSU HANSOH PHARMA CO LTD +2
Patent Information
- Application Number
- PCT/CN2024/129413
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-08
- Filing Date
- 2024-11-01
- Publication Date
- 2025-05-08
AI Technical Summary
Technical Problem
Current KRas inhibitors have not demonstrated sufficient safety and efficacy to obtain regulatory approval for treating KRas G12C-mediated cancer.
Method used
Development of a new scaffold of nitrogen-containing polycyclic compounds that selectively inhibit KRAS G12C, offering improved physiochemical properties.
Benefits of technology
The compounds provide a distinct chemotype with potential for delivering a KRAS G12C inhibitor that effectively treats KRas G12C-mediated cancer.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN2024129413_08052025_PF_FP_ABST
Abstract
Compounds of formula (I) useful as cancer treatment, the preparation method thereof, pharmaceutical compositions comprising the compounds, and the pharmaceutical uses for the treatment of certain diseases or disorders are disclosed.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
4-aminobutyl-2-alkenyl amide derivative and salt thereof
CN115551500A
Small molecule inhibitors of KRAS g12c mutant
WO2022232318A1
Small molecule inhibitors of KRAS g12c mutant
WO2022232320A1
Cited By
Macrocyclic compound, preparation methods and medicinal uses thereof
WO2025209490A1
Ras inhibitors
WO2025240847A1
Methods of treating a ras protein-related disease or disorder
WO2025255438A1
Therapeutic compositions and methods for managing treatment-related effects
WO2025265060A1
Ras inhibitors
WO2026006747A1